Corcept Therapeutics reported $8.99M in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
ANI Pharmaceuticals USD 607.23M 3.26M Sep/2026
Ardelyx USD 256.19M 47.93M Jun/2026
Aurora Cannabis CAD 22.68M 1.18M Jun/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Canopy Growth CAD 277.33M 1.38M Jun/2026
Corcept Therapeutics USD 8.99M 430K Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
J&J USD 49.04B 5.95B Jun/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Merck USD 53.91B 4.79B Jun/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 48.31B 1.31B Sep/2026
Omeros USD 442.16M 199K Sep/2023
Pacira USD 293.59M 69.53M Sep/2026
Pfizer USD 62.67B 523M Sep/2026
Supernus Pharmaceuticals USD 40.17M 733K Jun/2026
TG Therapeutics USD 754.37M 68K Sep/2026